<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02993913</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-CT-006I</org_study_id>
    <nct_id>NCT02993913</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid Tumor</brief_title>
  <official_title>A Safety, Tolerability and Pharmacokinetic Study of Single and Repeat Oral Escalating Doses of Simmiparib in Patients With Advanced Malignant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Acebright Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Acebright Pharmaceuticals Co., Ltd.</source>
  <brief_summary>
    <textblock>
      Phase I dose escalating trial. Primary objectives of this study are to assess the safety and&#xD;
      tolerability of Simmiparib following single and multiple oral doses in patients with advanced&#xD;
      solid malignancies, to determine the maximum tolerance dose (MTD) and dose limiting toxicity&#xD;
      (DLT), and pharmacokinetic profile.&#xD;
&#xD;
      The Secondary objective is to observe the preliminary antitumor effect of Simmiparib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-center, nonrandomized, open-label, dose-escalating study. The trial was divided&#xD;
      into dose escalation and expansion stages.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2016</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Per doselevel of 3 to 6 patients (When 3-6 patients have completed DLT periods of 4 weeks)</time_frame>
    <description>The Dose level at which more than 1/6 patients develop a Dose Limiting Toxicity (DLT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Cmax (maximum concentration)</measure>
    <time_frame>At day 1 single dose period, day 8 and 28 multiple dose period day</time_frame>
    <description>PK blood collection Before 0:00h and after 0.25h、0.50h、1:00h、1.50h、2:00h、3:00h、4:00h、6:00h、8:00h、10:00h、24:00h、48:00h、72:00h at single dose period.&#xD;
PK blood collection before 0:00h and after 0.25h、0.50、1:00h、1.50h、2:00h、3:00h、4:00h、6:00h、8:00h、10:00h and 12:00h at multiple dose period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Tmax (Time of maximum concentration)</measure>
    <time_frame>At day 1 single dose period, day 8 and 28 multiple dose period day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics AUC (Area Under the Curve)</measure>
    <time_frame>At day 1 single dose period, day 8 and 28 multiple dose period day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Poly ADP-ribose polymerase (PARP) inhibition measured by PAR assay</measure>
    <time_frame>Up to 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to 4 months</time_frame>
    <description>ORR according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malignant Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Simmiparib tablet monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Simmiparib tablet oral Qd or Bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simmiparib</intervention_name>
    <description>Simmiparib Tablets, oral administration</description>
    <arm_group_label>Simmiparib tablet monotherapy</arm_group_label>
    <other_name>SMOCL-9112</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients confirmed with advanced solid tumor based on pathology and/or cytology,&#xD;
             considered unresponsive or poorly responsive to standard therapies, no curative&#xD;
             therapies or can't tolerate standard therapies;&#xD;
&#xD;
          2. Patients must have measurable disease in accordance with RECIST criteria v. 1.1, at&#xD;
             least one lesion that can be accurately measured in CT and MRI at least one dimension&#xD;
             ( longest diameter≥10mm; if lymph node, short diameter≥15mm );&#xD;
&#xD;
          3. Age≥18 and ≤75 years, both men and women, no history of drug abuse and alcohol;&#xD;
&#xD;
          4. Life expectancy≥ 3 months and can be followed for safety and efficiency&#xD;
&#xD;
          5. Received no prior anti-tumor therapies at least within past 4 weeks and no other&#xD;
             adjuvant anti-tumor regimen(including steroids mediations )&#xD;
&#xD;
          6. Have recovered to≤ common terminology criteria of adverse events (CTC-AE) 1 from&#xD;
             toxicities of prior therapy&#xD;
&#xD;
          7. Not participated in any clinical trials within 28 days;&#xD;
&#xD;
          8. Not have received treatment of poly-ADP ribose polymerase (PARP) inhibitor;&#xD;
&#xD;
          9. No serious abnormal hematopoiesis function, has adequate cardiac, pulmonic, hepatic&#xD;
             and renal function. Blood routine and blood biochemical examination within 2 weeks&#xD;
             before enrollment : White blood cell (WBC) ≥4000/mm3, Absolute neutrophil count (ANC)&#xD;
             ≥1,500/mm3, Platelets ≥100,000/mm3, Coagulation function ≤ 1.5 times upper limit of&#xD;
             normal (ULN), serum creatinine ≤ 1.5 times ULN, Total bilirubin ≤ 1.5 times ULN,&#xD;
             Patients without liver metastasis, Aspartate aminotransferase (AST)/alanine&#xD;
             aminotransferase (ALT)≤ 2.5 times ULN; Patients with liver metastasis, Aspartate&#xD;
             aminotransferase (AST)/alanine aminotransferase (ALT)/≤ 2.5 times ULN, NYHAclass≤Ⅱand&#xD;
             Left ventricular ejection fraction ( LVEF)&gt;50%;&#xD;
&#xD;
         10. Virology test: negative HbsAg, HCV, HIV and syphilis&#xD;
&#xD;
         11. Eastern Cooperative Oncology Group(ECOG) performance status ≤2;&#xD;
&#xD;
         12. No history of other malignant tumors, except cervical carcinoma in situ, basal skin&#xD;
             cancer or squamous-cell carcinoma that have been cured; No other serious illnesses&#xD;
             that are in conflict with this study and significant heart disease and psychosis;&#xD;
&#xD;
         13. Ability to understand and a willingness to sign a written informed consent; Obtaining&#xD;
             consent before any operation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with serious medical disease, including, severe cardiopathy, vascular&#xD;
             disease, uncontrolled diabetes, uncontrolled hypertension, severe infection , or&#xD;
             psychosis, etc.;&#xD;
&#xD;
          2. Patients with primary brain lesion or metastases lesion;&#xD;
&#xD;
          3. Female patient who is pregnant, breast feeding or unwilling to contraception;&#xD;
&#xD;
          4. Patient who received or is receiving any other investigational agents within 4 weeks&#xD;
             prior to treatment;&#xD;
&#xD;
          5. Patients, with poor compliance, or based on the opinion of the investigator, should&#xD;
             not be enrolled into this study;&#xD;
&#xD;
          6. has not recovered to grade 1 or better from any adverse events related to previous&#xD;
             therapy.&#xD;
&#xD;
          7. Neurotoxicity observed in previous antineoplastic therapy has not recovered to grade 1&#xD;
             or below.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xichun Hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MohammadAbdul Kaium</last_name>
    <phone>0086-21-51323300</phone>
    <phone_ext>4080</phone_ext>
    <email>kaium@acebright.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Liu</last_name>
    <phone>0086-21-51323300</phone>
    <email>jian.liu@acebright.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xichun Hu, Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 6, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2016</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

